NasdaqCM - Delayed Quote USD

BeyondSpring Inc. (BYSI)

Compare
1.7900
+0.0200
+(1.13%)
At close: January 31 at 4:00:00 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BYSI

Recent News: BYSI

View More
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
GlobeNewswire 3 days ago
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
GlobeNewswire 3 days ago
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
GlobeNewswire 2 months ago
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
GlobeNewswire 4 months ago
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
GlobeNewswire 4 months ago
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine
GlobeNewswire 4 months ago
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
GlobeNewswire 4 months ago
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?

Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?
Simply Wall St. 4 months ago
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
GlobeNewswire 5 months ago
BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year

BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year
Simply Wall St. 8 months ago
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
GlobeNewswire 8 months ago
View More

Related Tickers

INTS Intensity Therapeutics, Inc.
2.2100
-1.78%
 
ADAG Adagene Inc.
1.9000
+2.70%
 
CNTB Connect Biopharma Holdings Limited
0.9720
-3.76%
 
VALN Valneva SE
5.78
+10.10%
 
IMUC EOM Pharmaceuticals Holdings, Inc.
0.1600
0.00%
 
GTBP GT Biopharma, Inc.
2.2300
+8.25%
 
LYEL Lyell Immunopharma, Inc.
0.5903
+1.22%
 
ADIL Adial Pharmaceuticals, Inc.
0.8300
0.00%
 
SABS SAB Biotherapeutics, Inc.
2.1900
+0.92%
 
ONCT Oncternal Therapeutics, Inc.
0.5266
-24.12%